Powering a New Wave of Immune Therapeutics

At Sonnet BioTherapeutics, we are developing targeted immuno-oncology drugs that turn ‘cold’ tumors ‘hot’. Our proprietary FHAB™ (Fully Human Albumin-Binding) technology empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.

About Sonnet BioTherapeutics

The Sonnet FHAB Mechanism of Action

Our modular FHAB construct utilizes a validated, targeted albumin-binding approach to deliver cytokine payloads with enhanced penetration, retention and local activation directly to the tumor.

Technology Platform

Technology Platform

Our FHAB platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.

Technology Platform
Pipeline

Pipeline

Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates.

Pipeline
Leadership

Leadership

The Sonnet team combines technical expertise in cytokine biology, as well as extensive experience in drug discovery and development.

Team

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today